US8431585B2 - Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy - Google Patents
Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy Download PDFInfo
- Publication number
- US8431585B2 US8431585B2 US12/706,819 US70681910A US8431585B2 US 8431585 B2 US8431585 B2 US 8431585B2 US 70681910 A US70681910 A US 70681910A US 8431585 B2 US8431585 B2 US 8431585B2
- Authority
- US
- United States
- Prior art keywords
- amino
- group
- quinazoline
- chloro
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- YHTNREZSEKQRLW-FHJHGPAASA-M COC1=CC2=NC=NC(N[RaH])=C2C=C1NC(=O)/C=C/C[Rb] Chemical compound COC1=CC2=NC=NC(N[RaH])=C2C=C1NC(=O)/C=C/C[Rb] YHTNREZSEKQRLW-FHJHGPAASA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/706,819 US8431585B2 (en) | 2002-05-11 | 2010-02-17 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10221018 | 2002-05-11 | ||
DE10221018A DE10221018A1 (de) | 2002-05-11 | 2002-05-11 | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
US38981502P | 2002-06-18 | 2002-06-18 | |
US10/431,699 US20030225079A1 (en) | 2002-05-11 | 2003-05-08 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
US11/609,407 US20070099918A1 (en) | 2002-05-11 | 2006-12-12 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
US12/706,819 US8431585B2 (en) | 2002-05-11 | 2010-02-17 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/609,407 Continuation US20070099918A1 (en) | 2002-05-11 | 2006-12-12 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100144639A1 US20100144639A1 (en) | 2010-06-10 |
US8431585B2 true US8431585B2 (en) | 2013-04-30 |
Family
ID=29285302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/706,819 Expired - Lifetime US8431585B2 (en) | 2002-05-11 | 2010-02-17 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
Country Status (11)
Country | Link |
---|---|
US (1) | US8431585B2 (de) |
EP (1) | EP1505981B1 (de) |
JP (1) | JP4630659B2 (de) |
AR (1) | AR039987A1 (de) |
AU (1) | AU2003233223A1 (de) |
CA (1) | CA2483590C (de) |
DE (1) | DE10221018A1 (de) |
PE (1) | PE20040400A1 (de) |
TW (1) | TW200407147A (de) |
UY (1) | UY27800A1 (de) |
WO (1) | WO2003094921A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04748B1 (et) | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
GEP20084551B (en) * | 2004-05-06 | 2008-11-25 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
EP1948180B1 (de) * | 2005-11-11 | 2013-03-13 | Boehringer Ingelheim International GmbH | Kombinationsbehandlung gegen krebs mit egfr/her2-hemmern |
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
PT1981863E (pt) | 2006-01-26 | 2012-12-07 | Boehringer Ingelheim Int | Processo para preparar derivados de quinazolina substituídos por aminocrotonilamino |
DK2068880T3 (da) | 2006-09-18 | 2012-07-23 | Boehringer Ingelheim Int | Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer |
UY31867A (es) | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
TWI385174B (zh) | 2008-11-10 | 2013-02-11 | Nat Health Research Institutes | 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物 |
SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
CN103254183B (zh) * | 2013-05-10 | 2015-11-11 | 苏州明锐医药科技有限公司 | 阿法替尼的制备方法 |
WO2014180271A1 (zh) * | 2013-05-10 | 2014-11-13 | 苏州明锐医药科技有限公司 | 阿法替尼及其中间体的制备方法 |
ES2773296T3 (es) * | 2013-10-23 | 2020-07-10 | Gemvax & Kael Co Ltd | Composición para tratar y prevenir la hiperplasia prostática benigna |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
AU2016333987A1 (en) | 2015-10-05 | 2018-05-10 | Ny State Psychiatric Institute | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies |
CN105669658B (zh) * | 2016-04-05 | 2018-06-29 | 北京民康百草医药科技有限公司 | 一种阿法替尼的精制方法 |
CN107488172B (zh) * | 2016-06-10 | 2020-06-12 | 山东新时代药业有限公司 | 一种阿法替尼的制备方法 |
Citations (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0566226A1 (de) | 1992-01-20 | 1993-10-20 | Zeneca Limited | Chinazolinderivate |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1997002266A1 (en) | 1995-07-06 | 1997-01-23 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
EP0799619A2 (de) | 1996-03-27 | 1997-10-08 | Pfizer Inc. | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von benigner Prostatahyperplasie |
WO1997038983A1 (en) | 1996-04-12 | 1997-10-23 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1998043960A1 (en) | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
US5866572A (en) | 1996-02-14 | 1999-02-02 | Zeneca Limited | Quinazoline derivatives |
WO1999009016A1 (en) | 1997-08-01 | 1999-02-25 | American Cyanamid Company | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
WO1999035146A1 (en) | 1998-01-12 | 1999-07-15 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
WO1999065228A2 (de) | 1998-06-09 | 1999-12-16 | Jenapharm Gmbh & Co. Kg | Pharmazeutische kombinationen zum ausgleich eines testosteron-defizits mit schutz der prostata |
WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
DE19911366A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6127374A (en) | 1997-07-29 | 2000-10-03 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
US6153617A (en) | 1997-07-29 | 2000-11-28 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
WO2000078735A1 (de) | 1999-06-21 | 2000-12-28 | Boehringer Ingelheim Pharma Kg | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2001034574A1 (en) | 1999-11-11 | 2001-05-17 | Osi Pharmaceuticals, Inc. | Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
EP1123705A1 (de) | 2000-02-09 | 2001-08-16 | Pfizer Products Inc. | Kombinationspräparate zur Behandlung von Funktionsstörungen des niederen Harnleiters |
WO2001068186A2 (en) | 2000-03-13 | 2001-09-20 | American Cyanamid Company | Use of cyanoquinolines for treating or inhibiting colonic polyps |
DE10017539A1 (de) | 2000-04-08 | 2001-10-11 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US20010044435A1 (en) | 2000-04-08 | 2001-11-22 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
DE10042060A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10042064A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6362336B1 (en) | 1995-12-18 | 2002-03-26 | Zeneca Limited | Chemical compounds |
WO2002041882A2 (en) | 2000-11-22 | 2002-05-30 | Novartis Ag | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20020077330A1 (en) | 2000-08-26 | 2002-06-20 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US20020082270A1 (en) | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
WO2002050043A1 (de) | 2000-12-20 | 2002-06-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US20020173509A1 (en) | 2000-12-20 | 2002-11-21 | Frank Himmelsbach | Quinazoline derivatives and phamaceutical compositions containing them |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
WO2003094921A2 (de) | 2002-05-11 | 2003-11-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von hemmern der egfr-vermittelten signaltransduktion zur behandlung von gutartiger prostatahyperplasie (bph)/prostatahypertrophie |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
US6673803B2 (en) | 1996-09-25 | 2004-01-06 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
WO2004096224A2 (de) | 2003-04-29 | 2004-11-11 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
US20050085495A1 (en) | 2003-10-17 | 2005-04-21 | Boehringer Ingelheim International Gmbh | Process for preparing amino crotonyl compounds |
US20050159436A1 (en) | 2002-04-19 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US20050215574A1 (en) | 2002-03-28 | 2005-09-29 | Bradbury Robert H | 4-anilino quinazoline derivatives as antiproliferative agents |
US6972288B1 (en) | 1999-02-27 | 2005-12-06 | Boehringer Ingelheim Pharma Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
WO2006018182A1 (en) | 2004-08-14 | 2006-02-23 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US7084136B2 (en) | 2000-06-02 | 2006-08-01 | Shionogi & Co., Ltd. | Drug composition antagonistic to both PGD2/TXA2 receptors |
US7160889B2 (en) | 2000-04-07 | 2007-01-09 | Astrazeneca Ab | Quinazoline compounds |
US7196091B2 (en) | 2003-06-06 | 2007-03-27 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
WO2007054551A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
WO2007085638A1 (en) | 2006-01-26 | 2007-08-02 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
WO2008034776A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
US20090203683A1 (en) | 2000-03-14 | 2009-08-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
WO2009147238A1 (en) | 2008-06-06 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Solid pharmaceutical formulations comprising bibw 2992 |
WO2010081817A1 (en) | 2009-01-14 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
WO2011003853A2 (en) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
WO2011069962A1 (en) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2280375T3 (es) * | 2000-04-08 | 2007-09-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Heterociclos biciclicos, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion. |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
PL2340253T3 (pl) * | 2008-09-30 | 2014-04-30 | SpecGx LLC | Sposoby selektywnego aminowania ketomorfinanów |
-
2002
- 2002-05-11 DE DE10221018A patent/DE10221018A1/de not_active Withdrawn
-
2003
- 2003-05-02 JP JP2004503006A patent/JP4630659B2/ja not_active Expired - Fee Related
- 2003-05-02 AU AU2003233223A patent/AU2003233223A1/en not_active Abandoned
- 2003-05-02 WO PCT/EP2003/004606 patent/WO2003094921A2/de active Application Filing
- 2003-05-02 CA CA2483590A patent/CA2483590C/en not_active Expired - Fee Related
- 2003-05-02 EP EP03727422A patent/EP1505981B1/de not_active Expired - Lifetime
- 2003-05-06 TW TW092112331A patent/TW200407147A/zh unknown
- 2003-05-09 UY UY27800A patent/UY27800A1/es not_active Application Discontinuation
- 2003-05-09 PE PE2003000451A patent/PE20040400A1/es not_active Application Discontinuation
- 2003-05-09 AR ARP030101622A patent/AR039987A1/es not_active Withdrawn
-
2010
- 2010-02-17 US US12/706,819 patent/US8431585B2/en not_active Expired - Lifetime
Patent Citations (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0566226A1 (de) | 1992-01-20 | 1993-10-20 | Zeneca Limited | Chinazolinderivate |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1997002266A1 (en) | 1995-07-06 | 1997-01-23 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US6362336B1 (en) | 1995-12-18 | 2002-03-26 | Zeneca Limited | Chemical compounds |
US5866572A (en) | 1996-02-14 | 1999-02-02 | Zeneca Limited | Quinazoline derivatives |
EP0799619A2 (de) | 1996-03-27 | 1997-10-08 | Pfizer Inc. | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von benigner Prostatahyperplasie |
WO1997038983A1 (en) | 1996-04-12 | 1997-10-23 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
US6344459B1 (en) | 1996-04-12 | 2002-02-05 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
US6673803B2 (en) | 1996-09-25 | 2004-01-06 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
WO1998043960A1 (en) | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6127374A (en) | 1997-07-29 | 2000-10-03 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
US6153617A (en) | 1997-07-29 | 2000-11-28 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
WO1999009016A1 (en) | 1997-08-01 | 1999-02-25 | American Cyanamid Company | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
WO1999035146A1 (en) | 1998-01-12 | 1999-07-15 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
DE19825591A1 (de) | 1998-06-09 | 1999-12-23 | Jenapharm Gmbh | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
US20070078091A1 (en) | 1998-06-09 | 2007-04-05 | Doris Hubler | Pharmaceutical combinations for compensating for a testosterone deficiency in men while simultaneously protecting the prostate |
WO1999065228A2 (de) | 1998-06-09 | 1999-12-16 | Jenapharm Gmbh & Co. Kg | Pharmazeutische kombinationen zum ausgleich eines testosteron-defizits mit schutz der prostata |
WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
US6972288B1 (en) | 1999-02-27 | 2005-12-06 | Boehringer Ingelheim Pharma Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
DE19911366A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US20120329778A1 (en) | 1999-06-21 | 2012-12-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20100069414A1 (en) | 1999-06-21 | 2010-03-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20020169180A1 (en) | 1999-06-21 | 2002-11-14 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20070185091A1 (en) | 1999-06-21 | 2007-08-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them |
US7220750B2 (en) | 1999-06-21 | 2007-05-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
WO2000078735A1 (de) | 1999-06-21 | 2000-12-28 | Boehringer Ingelheim Pharma Kg | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2001034574A1 (en) | 1999-11-11 | 2001-05-17 | Osi Pharmaceuticals, Inc. | Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
EP1123705A1 (de) | 2000-02-09 | 2001-08-16 | Pfizer Products Inc. | Kombinationspräparate zur Behandlung von Funktionsstörungen des niederen Harnleiters |
WO2001068186A2 (en) | 2000-03-13 | 2001-09-20 | American Cyanamid Company | Use of cyanoquinolines for treating or inhibiting colonic polyps |
US20090203683A1 (en) | 2000-03-14 | 2009-08-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US7160889B2 (en) | 2000-04-07 | 2007-01-09 | Astrazeneca Ab | Quinazoline compounds |
US20010044435A1 (en) | 2000-04-08 | 2001-11-22 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
DE10017539A1 (de) | 2000-04-08 | 2001-10-11 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7084136B2 (en) | 2000-06-02 | 2006-08-01 | Shionogi & Co., Ltd. | Drug composition antagonistic to both PGD2/TXA2 receptors |
DE10042060A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US20020082270A1 (en) | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE10042064A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6653305B2 (en) | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20020077330A1 (en) | 2000-08-26 | 2002-06-20 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
WO2002041882A2 (en) | 2000-11-22 | 2002-05-30 | Novartis Ag | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
US20110046168A1 (en) | 2000-12-20 | 2011-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods of treating diseases using quinazoline derivatives and pharmaceutical compositions containing them |
WO2002050043A1 (de) | 2000-12-20 | 2002-06-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US20020173509A1 (en) | 2000-12-20 | 2002-11-21 | Frank Himmelsbach | Quinazoline derivatives and phamaceutical compositions containing them |
US20100010023A1 (en) | 2000-12-20 | 2010-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
USRE43431E1 (en) | 2000-12-20 | 2012-05-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US20060100223A1 (en) | 2000-12-20 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US20050215574A1 (en) | 2002-03-28 | 2005-09-29 | Bradbury Robert H | 4-anilino quinazoline derivatives as antiproliferative agents |
US20080269487A1 (en) | 2002-03-28 | 2008-10-30 | Astrazeneca Ab | 4-anilino quinazoline derivatives as antiproliferative agents |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US20060270672A1 (en) | 2002-03-30 | 2006-11-30 | Frank Himmelsbach | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US7119084B2 (en) | 2002-03-30 | 2006-10-10 | Boehringer Ingelheim International Gmbh | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US20090036676A1 (en) | 2002-03-30 | 2009-02-05 | Frank Himmelsbach | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US20050159436A1 (en) | 2002-04-19 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
US20080103161A1 (en) | 2002-04-19 | 2008-05-01 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
US20070099918A1 (en) | 2002-05-11 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
WO2003094921A2 (de) | 2002-05-11 | 2003-11-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von hemmern der egfr-vermittelten signaltransduktion zur behandlung von gutartiger prostatahyperplasie (bph)/prostatahypertrophie |
US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
WO2004096224A2 (de) | 2003-04-29 | 2004-11-11 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
US20110039863A1 (en) | 2003-04-29 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
US7846936B2 (en) | 2003-04-29 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20080254040A1 (en) | 2003-04-29 | 2008-10-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20110171289A1 (en) | 2003-04-29 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
US7196091B2 (en) | 2003-06-06 | 2007-03-27 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
WO2005037824A2 (de) | 2003-10-17 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von aminocrotonylverbindungen |
US20070027170A1 (en) | 2003-10-17 | 2007-02-01 | Rainer Soyka | Process for preparing amino crotonyl compounds |
US20050085495A1 (en) | 2003-10-17 | 2005-04-21 | Boehringer Ingelheim International Gmbh | Process for preparing amino crotonyl compounds |
US20090238828A1 (en) | 2004-08-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations for the Treatment of Diseases involving Cell Proliferation |
WO2006018182A1 (en) | 2004-08-14 | 2006-02-23 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
WO2007054551A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
US20090306101A1 (en) | 2005-11-11 | 2009-12-10 | Flavio Solca | Combination treatment of cancer comprising egfr/her2 inhibitors |
US20090306044A1 (en) | 2005-11-11 | 2009-12-10 | Flavio Solca | Quinazoline derivatives for the treatment of cancer diseases |
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US7960546B2 (en) | 2006-01-26 | 2011-06-14 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US20110207932A1 (en) | 2006-01-26 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
WO2007085638A1 (en) | 2006-01-26 | 2007-08-02 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US8188274B2 (en) | 2006-01-26 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US20090306378A1 (en) | 2006-01-26 | 2009-12-10 | Juergen Schroeder | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US8067593B2 (en) | 2006-01-26 | 2011-11-29 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US20110207929A1 (en) | 2006-01-26 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
WO2008034776A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
US20090318480A1 (en) | 2006-09-18 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
WO2009147238A1 (en) | 2008-06-06 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Solid pharmaceutical formulations comprising bibw 2992 |
US20110142929A1 (en) | 2008-06-06 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Solid pharmaceutical formulations comprising bibw 2992 |
US20120157472A1 (en) | 2009-01-14 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
WO2010081817A1 (en) | 2009-01-14 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
US20120107399A1 (en) | 2009-07-06 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
WO2011003853A2 (en) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
WO2011069962A1 (en) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
US20130012465A1 (en) | 2009-12-07 | 2013-01-10 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
Non-Patent Citations (19)
Title |
---|
Abstract in English (2000) for DE19911366. |
Alan, Rick, "Benign Prostatic Hyperplasia (BPH)", available at http://healthlibrary.epnet.com/GetContent. aspx?token-1baaea3c-d4f5-4e14-8429-e3b3e1add7a7chunkiid-12003, 2006. |
Barton, J. et al., "Growth Factors and their Receptors: new Targets for Prostate Cancern Therapy". Urology 58 (Supplement 2A), Aug. 2001, p. 114-122. |
Bell, D.W. et al., "Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR". Nature Genetics, Dec. 2005, vol. 37, No. 12, p. 1315-1316. Published online Oct. 30, 2005. |
Cancer Genome and Collaborative Group. Nature, Brief Communications, Sep. 2004, vol. 431, p. 525-526. |
Duque, J.L. et al., "Heparin-Binding Epidermal Growth Factor-Like Growth Factor is an Autocrine Mediator of Human Prostate Stromal Cell Growth in Vitro". The Journal of Urology, vol. 165, Jan. 2001, p. 284-288. |
Gonzalez-Barcena et al.; Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer; The Prostate; 1994; 24(2); 84-92; only abstract provided. |
Harari, P.M. "Epidermal growth factor receptor inhibition strategies in oncology". Endocrine-Related Cancer, 2004, vol. 11. p. 689-708. |
Herbst, R.S. et al., "Monoclonal Antibodies to Target Epidermal Growth Factor Receptor-Positive Tumors". Cancer, Mar. 1, 2002, vol. 94, No. 5, p. 1593-1611. |
Hoffman; Chapter 10 Catecholamines, Sympathomimetic Drugs, and Adrenergic Receptor Antagonists; Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; Hardman JG; Limbird LD; and Gilman AG; Eds., McGraw-Hill; 2001; 215-268 (pp. 215, 247 and 248 provided). |
International Search Report for PCT/EP2003/04606 mailed Dec. 1, 2003. |
Krozely, P. Abstract-Clinical Journal of Oncology Nursing, 2004, vol. 8, No. 2, p. 1092-1095. |
Lee, Mary, "Tamsulosin for the Treatment of Benign Prostatic Hypertrophy," The Annals of Pharmacotherapy, Feb. 2000,vol. 34, pp. 188-199. |
Maria P. De Miguel et al., Immunohistochemical Comparative Analysis of Transforming Growth Factor alpha, Epidermall Growth Factor, and Epidermal LGrowth Factor Receptor in normal, hyperplastic and neoplastic human prostates, Cytokine Septemer 1999, vol. 11, No. 9, pp. 722-727. |
Paez, J. G. "EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy". Science, vol. 304, 2004, p. 1497-1500. |
Rayford et al.; Muscarinic cholinergic receptors promote growth of human prostate cancer cells; The Prostate; Feb. 1997; 30(3); 160-166. |
Tsou, Hwei-Ru, "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Facotr Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumore Activity", J. Med. Chem 2001, 2719-2734, vol. 44. |
U.S. Appl. No. 12/914,003, filed Oct. 28, 2010, Inventor: Frank Himmelsbach. |
Yanase, K. et al., "Gefitinib reverses breast cancer resistance protein-medicated drug resistance". Molecular Cancer Therapeutics, 2004, Vo. 9, No. 9, p. 119-1125. |
Also Published As
Publication number | Publication date |
---|---|
CA2483590C (en) | 2011-01-04 |
US20100144639A1 (en) | 2010-06-10 |
UY27800A1 (es) | 2003-12-31 |
EP1505981A2 (de) | 2005-02-16 |
WO2003094921A2 (de) | 2003-11-20 |
JP2005526123A (ja) | 2005-09-02 |
AR039987A1 (es) | 2005-03-09 |
DE10221018A1 (de) | 2003-11-27 |
EP1505981B1 (de) | 2012-07-11 |
TW200407147A (en) | 2004-05-16 |
WO2003094921A3 (de) | 2004-03-18 |
AU2003233223A1 (en) | 2003-11-11 |
JP4630659B2 (ja) | 2011-02-09 |
PE20040400A1 (es) | 2004-08-02 |
CA2483590A1 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8431585B2 (en) | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | |
US20070099918A1 (en) | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | |
CA2472293C (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
CN102459204B (zh) | 溶血磷脂酸受体的多环拮抗剂 | |
US20030144252A1 (en) | Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor | |
US20100029673A1 (en) | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | |
JP5585892B2 (ja) | キナーゼ阻害剤としての化合物 | |
US20070004720A1 (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
JP2010521473A (ja) | 血管形成阻害剤としての化合物 | |
ES2292461T3 (es) | Derivados de quinazolina. | |
JP2007502807A5 (de) | ||
JP2005526123A5 (de) | ||
KR20070117547A (ko) | 뇌암 치료방법 | |
CA2543649A1 (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
US20050059661A1 (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
DE102005005505A1 (de) | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung der chronischen Rhinosinusitis | |
CA2533752A1 (en) | Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes | |
WO2008046242A1 (fr) | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |